Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Axsome Therapeutics, Inc. | General Counsel | Performance Stock Units | 7.74K | $1.01M | $131.07 | Feb 24, 2025 | Direct |
Axsome Therapeutics, Inc. | General Counsel | Restricted Stock Units | 7.74K | $1.01M | $131.07 | Feb 21, 2025 | Direct |
Axsome Therapeutics, Inc. | General Counsel | Employee Stock Option (Right to Buy) | 23.6K | $82.6K | $3.50 | Feb 27, 2024 | Direct |
Axsome Therapeutics, Inc. | General Counsel | Employee Stock Option (Right to Buy) | 7.82K | Feb 21, 2025 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
AXSM | Axsome Therapeutics, Inc. | Feb 21, 2025 | 3 | $0 | 4 | Feb 25, 2025 | General Counsel |
AXSM | Axsome Therapeutics, Inc. | Feb 27, 2024 | 2 | $0 | 4 | Feb 29, 2024 | General Counsel |
AXSM | Axsome Therapeutics, Inc. | Mar 2, 2023 | 2 | $0 | 4 | Mar 6, 2023 | General Counsel |
AXSM | Axsome Therapeutics, Inc. | Jun 13, 2022 | 0 | $0 | 3 | Jun 15, 2022 | General Counsel |